Cargando…
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504716/ https://www.ncbi.nlm.nih.gov/pubmed/34634062 http://dx.doi.org/10.1371/journal.pone.0258093 |
_version_ | 1784581374564368384 |
---|---|
author | Boissel, Jean-Pierre Pérol, David Décousus, Hervé Klingmann, Ingrid Hommel, Marc |
author_facet | Boissel, Jean-Pierre Pérol, David Décousus, Hervé Klingmann, Ingrid Hommel, Marc |
author_sort | Boissel, Jean-Pierre |
collection | PubMed |
description | In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm. RCTs emerged mid-last century as the gold standard for assessing efficacy, becoming the cornerstone of the value of new therapies, yet their ethical grounds are a matter of debate. We introduce the concept of unnecessary participants in RCTs, the sum of non-informative participants and non-responders. The non-informative participants are considered not informative with respect to the efficacy measured in the trial in contrast to responders who carry all the information required to conclude on the treatment’s efficacy. The non-responders present the event whether or not they are treated with the experimental treatment. The unnecessary participants carry the burden of having to participate in a clinical trial without benefiting from it, which might include experiencing side effects. Thus, these unnecessary participants carry the ethical loss that is inherent to the RCT methodology. On the contrary, responders to the experimental treatment bear its entire efficacy in the RCT. Starting from the proportions observed in a real placebo-controlled trial from the literature, we carried out simulations of RCTs progressively increasing the proportion of responders up to 100%. We show that the number of unnecessary participants decreases steadily until the RCT’s ethical loss reaches a minimum. In parallel, the trial sample size decreases (presumably its cost as well), although the trial’s statistical power increases as shown by the increase of the chi-square comparing the event rates between the two arms. Thus, we expect that increasing the proportion of responders in RCTs would contribute to making them more ethically acceptable, with less false negative outcomes. |
format | Online Article Text |
id | pubmed-8504716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85047162021-10-12 Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample Boissel, Jean-Pierre Pérol, David Décousus, Hervé Klingmann, Ingrid Hommel, Marc PLoS One Research Article In order to propose a more precise definition and explore how to reduce ethical losses in randomized controlled clinical trials (RCTs), we set out to identify trial participants who do not contribute to demonstrating that the treatment in the experimental arm is superior to that in the control arm. RCTs emerged mid-last century as the gold standard for assessing efficacy, becoming the cornerstone of the value of new therapies, yet their ethical grounds are a matter of debate. We introduce the concept of unnecessary participants in RCTs, the sum of non-informative participants and non-responders. The non-informative participants are considered not informative with respect to the efficacy measured in the trial in contrast to responders who carry all the information required to conclude on the treatment’s efficacy. The non-responders present the event whether or not they are treated with the experimental treatment. The unnecessary participants carry the burden of having to participate in a clinical trial without benefiting from it, which might include experiencing side effects. Thus, these unnecessary participants carry the ethical loss that is inherent to the RCT methodology. On the contrary, responders to the experimental treatment bear its entire efficacy in the RCT. Starting from the proportions observed in a real placebo-controlled trial from the literature, we carried out simulations of RCTs progressively increasing the proportion of responders up to 100%. We show that the number of unnecessary participants decreases steadily until the RCT’s ethical loss reaches a minimum. In parallel, the trial sample size decreases (presumably its cost as well), although the trial’s statistical power increases as shown by the increase of the chi-square comparing the event rates between the two arms. Thus, we expect that increasing the proportion of responders in RCTs would contribute to making them more ethically acceptable, with less false negative outcomes. Public Library of Science 2021-10-11 /pmc/articles/PMC8504716/ /pubmed/34634062 http://dx.doi.org/10.1371/journal.pone.0258093 Text en © 2021 Boissel et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Boissel, Jean-Pierre Pérol, David Décousus, Hervé Klingmann, Ingrid Hommel, Marc Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title | Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title_full | Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title_fullStr | Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title_full_unstemmed | Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title_short | Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
title_sort | using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504716/ https://www.ncbi.nlm.nih.gov/pubmed/34634062 http://dx.doi.org/10.1371/journal.pone.0258093 |
work_keys_str_mv | AT boisseljeanpierre usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample AT peroldavid usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample AT decoususherve usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample AT klingmanningrid usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample AT hommelmarc usingnumericalmodelingandsimulationtoassesstheethicalburdeninclinicaltrialsandhowitrelatestotheproportionofrespondersinatrialsample |